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Abstract
Background: Transforming growth factor (TGF)-b is known to be produced by progressor tumors and to
immobilize dendritic cells (DCs) within those tumors. Moreover, although TGF-b1 has been shown to promote
tumor progression, there is still no direct, in vivo evidence as to whether TGF-b1 is able to directly induce distant
metastasis.
Methods: To address that issue and investigate the mechanism by which TGF-b1 suppresses DC activity, we
subdermally inoculated mouse ears with squamous cell carcinoma cells stably expressing TGF-b1 or empty vector
(mock).
Results: The numbers of DCs within lymph nodes draining the resultant TGF-b1-expressing tumors was
significantly lower than within nodes draining tumors not expressing TGF-b1. We then injected fluorescently
labeled bone marrow-derived dendritic cells into the tumors, and subsequent analysis confirmed that the tumors
were the source of the DCs within the tumor-draining lymph nodes, and that there were significantly fewer
immature DCs within the nodes draining TGF-b1-expressing tumors than within nodes draining tumors not
expressing TGF-b1. In addition, 14 days after tumor cell inoculation, lymph node metastasis occurred more
frequently in mice inoculated with TGF-b1 transfectants than in those inoculated with the mock transfectants.
Conclusions: These findings provide new evidence that tumor-derived TGF-b1 inhibits migration of DCs from
tumors to their draining lymph nodes, and this immunosuppressive effect of TGF-b1 increases the likelihood of
metastasis in the affected nodes.
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Background
Transforming growth factor (TGF) -b can reportedly
promote cancer metastasis by affecting the tumor
microenvironment in a manner that facilitates tumor
cell invasion [1,2] and by inhibiting immune cell func-
tion [3]. Consistent with those reports, overproduction
of TGF-b by tumors is frequently associated with metas-
tasis [4-6] and a poor prognosis in patients with cancer
[7-10]. Among the three highly homologous TGF-b
isoforms, TGF-b1 is the most abundant and most exten-
sively studied [11]. We previously showed that tumor-
derived TGF-b1c a u s e sar e d u c t i o ni nt h en u m b e ro f
dendritic cells (DCs) within tumor-draining lymph
nodes (TDLNs) [12]. It also has been shown that TGF-
b1 is produced by progressor tumors and that it immo-
bilizes the DCs within those tumors [13]. This is note-
worthy because DCs are highly specialized, antigen-
presenting cells that play a crucial role in the initial acti-
vation and subsequent regulation of immune responses,
and are important for the induction of tumor immunity;
they take up antigen within the tumor and migrate to
local lymph nodes, where they present the antigen to T
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in an immunogenic or tolerogenic manner and are a
crucial determinant of the host response to tumors.
Indeed, tumors are immunologically destroyed when
DCs are able to take up antigen and migrate to the
lymph nodes, but escape destruction if the DCs are sub-
verted so that they do not migrate to the draining
lymph nodes, or if macrophages become the major cell
taking up antigen [13,14].
In addition, Cui et al. found that expression of the
TGF-b1t r a n s g e n ei n h i b i t e db enign tumor formation,
but enhanced progression of carcinomas [15]. It is still
not known at which stage or by what mechanisms TGF-
b1 switches from a tumor suppressor to a tumor pro-
moter. Moreover, no direct in vivo evidence document-
ing whether TGF-b1 directly induces distant metastasis
has yet been reported. To address these issues, we gen-
erated a carcinoma stably overexpressing a TGF-b1
transgene. Here we provide in vivo evidence that expres-
sion of TGF-b1 may directly induce metastasis in
tumors that escape the immune response of DCs, and
that down-regulation of DC migration from the tumor
to its TDLNs is a key event fostering metastasis.
Materials and methods
Mice
Male 6-week-old syngeneic C3H/He N mice were
obtained (The Jackson Laboratory, Bar Harbor, Maine)
and maintained in accordance with the guidelines of the
Committee on Animals of the Akita University School
of Medicine.
Tumor cell lines
SCCVII is a spontaneously arising squamous cell cancer
of C3H mice. SCCVII cells were maintained at 37°C in
complete medium (CM: RPMI-1640 medium with 2
mM L-glutamine and 1 mM sodium pyruvate) supple-
mented with 10% FBS, 100 units/ml penicillin G, 0.1
mg/ml streptomycin and 0.5 μg/ml amphotericin B
under a humidified atmosphere of 95% air and 5% CO2.
Establishment of Stable TGF-b1 Transfectants
A cDNA clone encoding full-length mouse TGF-b1
mRNA (GenBank accession no. BC013738) in the
pCMV-SPORT6 vector was purchased from OpenBio-
systems (Huntsville, AL) and subcloned into pIRES2-
AcGFP1 vector (Clontech, Inc. Palo Alto, CA). The
IRES2-AcGFP1 vector harboring TGF-b1 was then
transfected into SCCVII cells using Lipofectamine 2000
reagent (Life Technologies, Inc. Grand Island, NY).
TGF-b1 transfectants were selected by culture for 2
weeks in medium containing 400 μg/ml G418 (Life
Technologies, Inc.); the resistant clones were then
obtained using the method of limiting dilution. As a
negative control, SCCVII cells were transfected with
pIRES2-AcGFP1 vector without the inserted TGF-b1
cDNA. The levels of TGF-b1e x p r e s s i o ni nt h es t a b l e
transfectants were then determined using RT-PCR and
an ELISA (R&D Systems Inc., Minneapolis, MN). For
RT-PCR, total RNA was isolated from the samples using
a Fast RNA Kit Green (Qbiogene, Carlsbad, CA) accord-
ing to the manufacturer’s instructions. After quantifying
the isolated RNA using a spectrophotometer, 1-μg ali-
quots were reverse transcribed using Superscript II
reverse transcriptase (Gibco BRL, Gaithersburg, Md.,).
The following primer sets were used: for TGF-b1, 5’-
ATCTCGAGCTCCGCCATGCCGCCCTCGGGG-3’
(forward) and 5’-TCGACTGCAGAATTCTCAGCTG-
CACTTGCA-3’ (reverse); for AcGFP1, 5’-GAGCTGTT-
CACCGGCATCGT-3’ (forward) and 5’-GATGGGGGT
ATTCTGCTGGT-3’ (reverse).
Cultured bone marrow-derived DCs
Bone marrow-derived DCs (bmDCs) were generated
using the method previously described by Labeur et al.,
with some modification [16]. Briefly, bone marrow was
collected from the tibias and femurs of male C3H/He N
mice, passed through a 100-μm nylon mesh to remove
small pieces of bone and debris, resuspended in CM,
and plated in tissue culture dishes for 2 h. Nonadherent
cells were collected and plated at a density of 2 × 10
6
cells/well in 6-well plates containing 1 ml of CM. Then
on days 0, 3 and 5, two-thirds of the medium were
replaced with CM containing 20 ng/ml recombinant
murine GM-CSF (Peprotech, Rocky Hill, NJ). By day 8
of culture, most of the nonadherent cells had acquired
typical DC morphology, and those cells were used as the
source of bmDCs. For in vitro experiments, 1 μg of lipo-
polysaccharide (LPS; Sigma-Aldrich Flanders NJ) was
added to the CM on day 7; then after an additional 48 h
the mature bmDCs were used. At the end of the proce-
dure, DC purity was assessed based on CD11c expres-
sion using single color flow cytometry and was found to
be 90% or greater.
TDLN cell preparation
To prepare TDLNs, tumor cells (1 × 10
6 cells/mouse)
were inoculated unilaterally into the ears of C3H/He N
mice. Fourteen days after inoculation, the mice were
killed, and the neck lymph nodes from the side bearing
the ear tumor (TDLNs) and from the side without the
tumor (non-TDLNs) were aseptically excised. Lympho-
cyte suspensions were then prepared by teasing apart
the nodes to release the cells and then passing the cell
suspension through a 100-μm nylon mesh. Erythrocytes
were lysed using ACK cell lysis buffer (0.15 M N4HCl,
10 mM KHCO3 and 0.1 mM EDTA). The cells were
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and 2 mM EDTA.
CFSE labeling of DCs
bmDCs isolated from C3H/He N mice were used as the
source of donor DCs in the transfer experiments. Cells
were resuspended in PBS at a concentration of 10
7
cells/ml and incubated with carboxyfluorescein diacetate
succinimidyl ester (CFSE; Molecular Probes Eugene,
OR) at a final concentration of 5 μM for 8 min at 37°C,
followed by two washes with RPMI 1640 medium con-
taining 10% FCS. Cell division was assessed using flow
cytometry by monitoring the dilution of CFSE labeling.
Injection of bmDCs
Labeled bmDCs were injected into the tumors 13 days
after tumor cell inoculation. Each tumor was injected
with 1 × 10
6 bmDCs in 100 μlo fP B S .T h eT D L N s
were then harvested 24 h after injection, and the num-
bers of bmDCs within the harvested nodes were counted
using flow cytometry.
Flow cytometry
Spleens and TDLNs were excised at the indicated times
after tumor cell inoculation. Each sample from an indi-
vidual mouse was separately prepared and analyzed; i.e.,
there was no pooling of lymph node cells. Flow cyto-
metric analysis was performed using a Cytomics FC500
(Beckman Coulter, Fullerton, CA). For analysis of DCs,
samples were stained with PE-conjugated anti-CD11c
and FITC-conjugated anti-CD86 (BD PharMingen, San
Diego, CA). In each sample, 100,000 events were routi-
nely acquired and analyzed using a Cytomics FC 500
with CXP Software (Beckman Coulter) to determine the
percentage of DCs and CFSE+ bmDCs within the lymph
nodes of each clone. Samples from at least ten indivi-
dual mice were analyzed for each time point unless
otherwise stated.
Quantitative real-time PCR
The primer sequences used to amplify murine TGF-b1
mRNA were 5’-TGGAGCAAC ATGTGGAACTC -3’
(left) and 5’-GTCAGCAGCCGGTTACCA -3’ (right),
and Universal Probe Library #72 (Roche Diagnostics,
Mannheim, Germany). All of the amplifications were
performed with Light cycler 480 systems (Roche Diag-
nostics) in a 20-μl final volume, for 45 cycles of dena-
turation at 95°C for 10 s, annealing at 60°C for 30 s and
elongation at 72°C for 1 s. As an internal control, we
also amplified murine b-actin mRNA (GenBank acces-
sion no. M12481.1) using primers 5’-CTGGCTCCTAG-
CACCATGA -3’ (left) and 5’-ACAGTGAGGCCA
AGATGGAG -3’ (right) and Universal Probe Library
#63 (Roche Diagnostics). After proportional background
adjustment, the fit point method was used to determine
the cycle in which the log-linear signal was distinguish-
able from the background, and that cycle number was
used as the crossing-point value. Levels of murine TGF-
b1 mRNA were then normalized to those of b-actin.
Analysis of TDLN metastasis
To assess lymph node metastasis, real-time PCR analysis
of AcGFP1 mRNA expression was carried out using a
Light Cycler 480 (Roche Diagnostics). pIRES2-AcGFP1
vector mRNA was amplified using primers 5’-TGATC-
TACTTCGGCTTCGTG -3’ (left) and 5’-CACTTGTA-
CAGCTCATCCATG C -3’ (right) and Universal Probe
Library #70 (Roche Diagnostics). In addition, to further
confirm the result, metastasis was assessed based on
immunohistochemical staining using anti-AcGFP1
(Clontech Laboratories) and goat polyclonal anti-cyto-
keratin (CK)-19 antibodies (Santa Cruz Biotechnology,
Inc, Santa Cruz, CA, USA).
Statistics
Values are expressed as means ± SD. Groups were com-
pared using one-way ANOVA in combination with
Dunnette’s methods and paired t test. Values of p < 0.05
were considered significant.
Results
After stably transfecting SCCVII cells with murine
TGFb1 cDNA, we initially confirmed the overexpression
of TGF-b1 protein by the transfectants. Using RT-PCR
with primers for full-length TGF-b1 or AcGFP1 gene,
we confirmed the presence of two empty vector-trans-
fected controls (M1, M2) and three TGF-b1-transfected
clones (T1, T2, T3) (Figure 1A). When levels of TGF-b1
mRNA were measured using real time PCR (Figure 1B),
tumors in mice inoculated with a TGF-b1t r a n s f e c t a n t
clone showed significantly higher levels of TGF-b1
mRNA than those inoculated with a mock transfectant.
In addition, when levels of TGF-b1 protein were mea-
sured in cultured cells using ELISAs (Table 1), only
TDLN lysates from mice bearing a TGF-b1-expressing
tumor showed high levels of TGF-b1( F i g u r e2 A ) .B y
contrast, serum TGF-b1 levels did not differ between
mice bearing tumors that expressed TGF-b1a n dt h o s e
did not (Figure 2B).
To begin assessing DC-mediated immunity in this
model, we used flow cytometry to determine the num-
bers and phenotypes of DCs within the TDLNs and
non-TDLNs from wild SCCVII tumor-bearing mice on
day 14 after tumor implantation. Figure 3A shows that
TDLNs from these mice contained approximately 1.5 to
5 times as many CD11c+ DCs as non-TDLNs. Numbers
of CD11c+CD86+ mature DCs were also increased 1.5
to 5 times within TDLNs, as compared to non-TDLNs
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antigen was higher in TDLNs than in non-TDLNs.
To assess the inhibition of DC migration into TDLNs by
tumor-derived TGF-b1, we used flow cytometry to count
the numbers of DCs within TDLNs and non-TLDNs. We
found that migration of DCs into TDLNs was inhibited in
mice inoculated with the three TGF-b1-expressing clones,
resulting in a significant reduction in the numbers of
CD11c+ DCs within TDLNs (Figure 4A). By contrast,
there was no significant difference between the numbers
of CD11+ DCs in non-TDLNs from mice inoculated with
mock or TGF-b1 transfectants. To identify the maturation
Figure 1 Characterization of TGF-b1 transfectant clones. TGF-b1
gene transfection was confirmed by RT-PCR and real-time RT-PCR.
A, Expression of TGF-b1 and AcGFP1 mRNA was assessed by RT-PCR.
Electrophoresis gels (a and b) show the expression of TGF-b1 and
AcGFP1 mRNA, respectively. M1 and M2, mock; T1, T2 and T3, TGF-
b1 transfectant clone; N, negative control (SCCVII cells). B, Relative
levels of murine TGF-b1 mRNA were determined by semi-
quantitative real-time RT-PCR. Levels of TGF-b1 mRNA were
normalized to those of b-actin mRNA and were found to be
significantly higher in TGF-b1 transfectants.
Table 1 Level of TGF-b1 expression in SCCVII cells
measured using an ELISA
Cultured cell
supernatants
TGF-b1 concentration (pg/mg
protein)
Statistics
Wild 183.31 ± 16.91
Mock transfectants
1 216.39 ± 6.33
2 213.94 ± 10.04
TGF-b1 transfectants
clone 1 541.35 ± 7.67 P < 0.01
clone 2 392.06 ± 8.65 P < 0.01
clone 3 380.12 ± 20.12 P < 0.01
Figure 2 Concentrations of TGF-b1 in tumor draining lymph
nodes. A, TGF-b1 levels in tumor-draining lymph nodes (TDLNs)
and the contralateral nodes (non-TDNLs) in the same mice were
assessed using an ELISA. Prior to inoculation, tumor cells were
transfected with either TGF-b1 gene or empty vector (mock). Note
that in mice inoculated with TGF-b1-transfectants, TGF-b1 levels
were higher in TDLNs than non-TDNLs. TGF-b1 levels were also
higher in TDLNs draining TGF-b1-expressing tumors than tumors
not expressing TGF-b1. B, Serum TGF-b1 levels measured in the
same mice as in panel A. Serum TGF-b1 levels did not differ among
the groups. *P < 0.05. n = 5 in each group.
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Page 4 of 9Figure 3 Increases in the number and biological activity of DCs within TDLNs in wild SCCVII tumor-bearing mice. A, Numbers of CD11c
+ DCs in TDLNs and non-TDLNs on day 14 after tumor inoculation. B, Numbers of CD11c+CD86+ mature DCs in TDLNs and non-TDLNs. The
immune response of DCs to tumor antigen was higher in TDLNs than non-TDLNs. *P < 0.05. n = 10 in each group.
Figure 4 Tumor-derived TGF-b1 reduces the number of DCs within TDLNs. A, Numbers of CD11c+ DCs in TDLNs and non-TDNLs from
mice inoculated with TGF-b1-tranfected or mock-transfected tumor cells. B, TDLN/non-TDLN ratios for CD11c+ DCs in mice inoculated with TGF-
b1-transfected or mock-transfected cells. C, To determine the maturation status of DCs within TDLNs, numbers of CD11c+ and CD86+ DCs were
counted, after which the TDLN/non-TDLN ratio for CD11c+CD86+ DCs was calculated. * P < 0.05.
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numbers of CD11c+ and CD86+ DCs. We found that the
TDLN/non-TDLN ratio for both CD11c+ cells and CD86
+CD11c+ mature DCs was reduced in mice inoculated
with TGF-b1-expressing clones (Figure 4B, C).
To further clarify the mechanism underlying the
r e d u c t i o ni nt h en u m b e r so fD C sw i t h i nT D L N s ,w e
injected the tumors with CFSE-labeled bmDCs and then
counted the numbers of labeled cells within the TDLNs.
With this method, we were able to distinguish migrated
CFSE-labeled bmDCs from autologous DCs within
TDLNs. Flow cytometric analysis of the TDLNs showed
that significantly fewer immature (no added LPS) CFSE
+ bmDCs migrated from TGF-b1-expressing tumors
than from mock-transfected tumors (Figure 5A). By
contrast, the total numbers of mature CFSE+ LPS-
induced bmDCs did not significantly differ between
TDLNs draining mock-and TGF-b1-transfected tumors
(Figure 5B). Thus, TGF-b1 suppressed the acquisition
by immature DCs of migratory capacity toward lymph
nodes.
Finally, to assess TDLN metastasis, we performed
real time PCR analysis of AcGFP1 expression in
TDLNs draining mock-and TGF-b1-transfected
tumors. By day 7 after implantation, metastasis was
evident in TDLNs from 2 of 5 mice inoculated with
TGF-b1 transfectant clone-1. By day 14, metastasis was
detected 3 of 5 TDLNs from mice implanted with
TGF-b1 transfectant clone-1 and in the same number
of nodes from mice implanted with TGF-b1t r a n s f e c -
tant clone-2. On the other hand, no metastasis was
detected in TDLNs from mice implanted with mock-
transfected clones (Figure 6A).
To confirm the metastasis, we immunohistochemically
stained TDLNs with anti-AcGFP1 and anti-CK-19 anti-
bodies. On day 14, AcGFP1+ and CK-19+ cell clusters
were found in TDLNs from mice implanted with TGF-
b1 transfectant clone-1 or clone-2 (Figure 6B). However,
no AcGFP1+ or CK-19+ clusters were detected in
TDLNs from mice implanted with a mock-transfectant
clone (Figure 6C). Apparently, expression of TGF-b1b y
tumor cells increases the likelihood of TDLN metastasis.
Discussion
In this report we demonstrated that overexpression of
TGF-b1 by tumor cells increased the likelihood of
metastasis to TDLNs. We also demonstrated that the
overexpressed TGF-b1 inhibited DC migration from
tumors into TDLNs. Together, these findings suggest
that inhibition of DC migration toward TDLNs by
tumor-derived TGF-b1 facilitates lymph node metastasis
in TDLNs.
Our observation that TGF-b1-expressing tumor cells
metastasized to TDLNs is consistent with the clinical
evidence, which shows that high levels of TGF-b1a r e
related to the lymph node metastasis [17,18]. TGF-b
plays a critical dual role in the progression of cancer.
During the early phase of tumor progression, TGF-b
acts as a tumor suppressor. Later, however, TGF-b pro-
motes processes that support tumor progression, includ-
ing tumor cell invasion, dissemination and immune
evasion [19]. In this study we also demonstrated that
overexpressed TGF-b1 inhibits DC migration from
tumors to TDLNs. Because DCs play a key role in cell-
mediated immunity by acting as an antigen-presenting
cell, a TGF-b1-induced reduction in DC migration into
TDLNs would be expected have an immunosuppressive
effect within TDLNs, thereby promoting tumor metasta-
sis into TDLNs.
Following injection of CFSE-labeled DCs into SCCVII
tumors, the numbers of labeled DCs that migrated into
TDLNs from tumors expressing TGF-b1 was lower than
the numbers that migrated from tumors not expressing
TGF-b1. TGFb1 can immobilize DCs, interfering with
their migration and thus the transport of antigen to
draining lymph nodes for presentation to adaptive
immune cells. Although we do not provide direct evi-
dence of the mechanism by which TGF-b1 inhibits DC
migration toward TDLNs in this study, Weber et al.
reported that TGFb1 inhibits DC migration from skin
tumors to draining lymph nodes, based on the disap-
pearance of E-cadherin+ DCs from draining lymph
nodes consistent with our results [20]. Moreover, Ogata
et al. demonstrated that TGF-b1 not only inhibits
expression of CCR7 on DCs, it also inhibits chemokine-
mediated DC migration in vitro [17]. We therefore con-
clude that tumor-derived TGF-b1 inhibits DC migration
from tumors to TDLNs.
In further investigating the role of TGF-b in metasta-
sis, mice models of metastasis have revealed that sys-
temic inhibition of the TGF-b signaling pathway
negatively affects metastasis formation. Consistent with
our hypothesis, several independent groups by Padua D
et al. and reference therein [21] have found that small-
molecule inhibitor of the TGF-b receptors (TGFBR)
type I with a human breast cancer cell line, and TGF-b
antagonist of the soluble TGFBR2 in a transgenic model
decrease the cancer’s metastatic capacity. These results
illustrate the capacity to target the TGF-b pathway in
order to effectively inhibit metastatic events [21]. How-
ever, given the clinical and experimental evidence that
TGF-b acts as a tumor suppressor, other groups have
argued that TGF-b functions as an inhibitor of epithelial
tumor growth and metastasis. In the example, loss of
TGFBR2 in mammary epithelial cells or fibroblasts
increased tumor formation and enhanced many markers
of tumor progression [22]. TGFBR2 knockout animals
developed significantly more pulmonary metastases [23].
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Page 6 of 9Figure 5 Tumor-derived TGF-b1 suppresses migration of immature DCs from tumors to TDLNs.A ,T oa s s e s sm i g r a t i o no fD C sf r o m
tumors to TDLNs, cultured bone-marrow dendritic cells (bmDCs) were labeled with CFSE and injected into the tumors. Shown are numbers of
CFSE-labeled bmDCs within TDLNs counted by flow cytometry 24 h after injection. B, To clarify the maturation status of the migrated bmDCs,
untreated immature CFSE-labeled bmDCs and LPS-treated mature CFSE-labeled bmDCs were injected. Note that the numbers of immature
bmDCs migrating from TGF-b1-transfected tumors was lower than from mock-transfected tumors, whereas there was no significant difference
between the numbers of migrated mature bmDCs. n = 10 in each group. LPS, lipopolysaccharide.
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Page 7 of 9Figure 6 Tumor derived TGF-b1 induced tumor metastasis in TDLNs. A, To evaluate tumor metastasis to TDLNs, expression of AcGFP1
mRNA within TDLNs was assessed by RT-PCR. B, Metastasis was confirmed by immunohistochemical detection of CK19 and AcGFP1 within
TDLNs draining TGF-b1-expressing tumors (left panel, clone 1; right panel, clone 2). C, Immunohistochemical detection of CK19 and AcGFP1 in
TDLNs draining mock-transfected tumors. Note the absence of metastasis in TDLNs draining tumors not expressing TGF-b1.
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levels of TGF-b1 most likely secreted by myeloid sup-
pressor cells [24]. These authors argue that the TGF-
b1 may provide an additional boost to tumor progres-
sion by dampening the immune response to the
tumors. Here we provide new direct evidence for such
an effect.
In the present study we did not directly prove that the
reduction in DCs migration causes tumor metastasis
into TDLNs. In addition to its immunosuppressive
effect, TGF-b1 upregulates cell motility and invasive-
ness, as well as epithelial-to-mesenchymal transition
[19]. These effects may have also promoted lymph node
metastasis in our study. Further investigation will be
needed to more precisely define the role of tumor-
derived TGF-b1 in tumor lymph node metastasis.
Conclusions
In sum, we have shown that overexpression of TGF-b1
by tumor cells promotes tumor metastasis into TDLNs,
most likely by inhibiting DC migration from tumors
towards TDLNs. This immunosuppressive effect would
be expected to promote lymph node metastasis in
patients with malignant disease.
Author details
1Department of Chest, Breast and Endocrinologic Surgery, Akita University
Graduate School of Medicine, 1-1-1 Hondo Akita City 010-8543, Japan.
2Department of Biochemistry, Akita University Graduate School of Medicine,
1-1-1 Hondo Akita City 010-8543, Japan.
Authors’ contributions
KI did animal experiments, flow cytometry work, and analyzed data and
wrote the paper. YM designed the research. SK and TS made TGF-β1
transfected SCCVII cell line. MI, HS, YS and SM performed contributed data
analysis. JO contributed experimental design and data analysis. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 20 December 2011 Accepted: 10 January 2012
Published: 10 January 2012
References
1. Giampieri S, Pinner S, Sahai E: Intravital imaging illuminates transforming
growth factor beta signaling switches during metastasis. Cancer Res 2010,
70:3435-3439.
2. Korpal M, Kang Y: Targeting the transforming growth factor-beta
signaling pathway in metastatic cancer. Eur J Cancer 2010, 46:1232-1240.
3. Teicher BA: Transforming growth factor-beta and the immune response
to malignant disease. Clin Cancer Res 2007, 13:6247-6251.
4. Leivonen SK, Kähäri VM: Transforming growth factor-beta signaling in
cancer invasion and metastasis. Int J Cancer 2007, 121:2119-2124.
5. Han G, Lu SL, Li AG, He W, Corless CL, Kulesz-Martin M, Wang XJ: Distinct
mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal
transition and metastasis during skin carcinogenesis. J Clin Invest 2005,
115:1714-1723.
6. Angenete E, Langenskiöld M, Palmgren I, Falk P, Oresland T, Ivarsson ML:
Transforming growth factor beta-1 in rectal tumour, mucosa and plasma
in relation to radiotherapy and clinical outcome in rectal cancer
patients. Int J Colorectal Dis 2007, 22:1331-1338.
7. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A: Transforming
growth factor beta1 is associated with angiogenesis, metastasis, and
poor clinical outcome in prostate cancer. Prostate 1998, 37:19-29.
8. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K:
Transforming growth factor-beta1 level correlates with angiogenesis,
tumor progression, and prognosis in patients with nonsmall cell lung
carcinoma. Cancer 2001, 91:964-971.
9. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N: The
expression of transforming growth factor-beta1 is significantly
correlated with the expression of vascular endothelial growth factor and
poor prognosis of patients with advanced gastric carcinoma. Cancer
1999, 86:1455-1462.
10. Robson H, Anderson E, James RD, Schofield PF: Transforming growth
factor beta 1 expression in human colorectal tumours: an independent
prognostic marker in a subgroup of poor prognosis patients. Br J Cancer
1996, 74:753-758.
11. Flanders KC, Wakefield LM: Transforming growth factor-(beta)s and
mammary gland involution; functional roles and implications for cancer
progression. J Mammary Gland Biol Neoplasia 2009, 14:131-144.
12. Ito M, Minamiya Y, Kawai H, Saito S, Saito H, Nakagawa T, Imai K,
Hirokawa M, Ogawa J: Tumor-derived TGF beta-1 induces dendritic cell
apoptosis in the sentinel lymph node. J Immunol 2006, 176:5637-5643.
13. Halliday GM, Le S: Transforming growth factor-beta produced by
progressor tumors inhibits, while IL-10 produced by regressor tumors
enhances, Langerhans cell migration from skin. Int Immunol 2001,
13:1147-1154.
14. Byrne SN, Halliday GM: Dendritic cells: making progress with tumour
regression? Immunol Cell Biol 2002, 80:520-530.
15. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ: TGFb1
inhibits the formation of benign skin tumors, but enhances progression
to invasive spindle carcinomas in transgenic mice. Cell 1996, 86:531-542.
16. Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, Grabbe S:
Generation of tumor immunity by bone marrow-derived dendritic cells
correlates with dendritic cell maturation stage. J Immunol 1999,
162:168-175.
17. Ogata M, Zhang Y, Wang Y, Itakura M, Zhang YY, Harada A, Hashimoto S,
Matsushima K: Chemotactic response toward chemokines and its
regulation by transforming growth factor-beta1 of murine bone marrow
hematopoietic progenitor cell-derived different subset of dendritic cells.
Blood 1999, 93:3225-3232.
18. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N: An
elevated serum level of transforming growth factor-beta 1 (TGF-beta 1)
significantly correlated with lymph node metastasis and poor prognosis
in patients with gastric carcinoma. Anticancer Res 2000, 20:4489-4493.
19. Meulmeester E, Ten Dijke P: The dynamic roles of TGF-β in cancer. J
Pathol 2011, 223:205-218.
20. Weber F, Byrne SN, Le S, Brown DA, Breit SN, Scolyer RA, Halliday GM:
Transforming growth factor-beta1 immobilises dendritic cells within skin
tumours and facilitates tumour escape from the immune system. Cancer
Immunol Immunother 2005, 54:898-906.
21. Padua D, Massagué J: Roles of TGF beta in metastasis. Cell Res 2009,
19:89-102.
22. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R,
Arteaga CL, Neilson EG, Hayward SW, Moses HL: Loss of TGF-beta type II
receptor in fibroblasts promotes mammary carcinoma growth and
invasion through upregulation of TGF-alpha-, MSP-and HGF-mediated
signaling networks. Oncogene 2005, 24:5053-5068.
23. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR,
Muller WJ, Moses HL: Effect of conditional knockout of the type II TGF-
beta receptor gene in mammary epithelia on mammary gland
development and polyomavirus middle T antigen induced tumor
formation and metastasis. Cancer Res 2005, 65:2296-2302.
24. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP,
Matrisian LM, Richmond A, Lin PC, Moses HL: Abrogation of TGF beta
signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells
that promote metastasis. Cancer Cell 2008, 13:23-35.
doi:10.1186/1756-9966-31-3
Cite this article as: Imai et al.: Inhibition of dendritic cell migration by
transforming growth factor-b1 increases tumor-draining lymph node
metastasis. Journal of Experimental & Clinical Cancer Research 2012 31:3.
Imai et al. Journal of Experimental & Clinical Cancer Research 2012, 31:3
http://www.jeccr.com/content/31/1/3
Page 9 of 9